Clinical research group Icon has reported pre-tax profits of $15.7m for the first three months of the year, up from $10.7m in the same period a year earlier.
Revenues rose by 38% to $136m and the company said it won a record $223m worth of new business in the period. As a result, Icon has lifted its full-year revenue estimate from $530-550m to $560-580m.
Icon provides development services to the pharmaceutical, biotechnology and medical device industries.
